Cardinal Health Aktie News

Key Points in This Article: Holding onto stocks that have significantly appreciated, rather than cashing out for short-term gains, preserves long-term portfolio growth and avoids capital gains taxes.

DUBLIN, Ohio , July 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2025 on August 12, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

DUBLIN, Ohio , July 11, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts.   This investment furthers Cardinal Health's longstanding advocacy around the futu...

Dividend stocks are a favorite among investors for good reason.

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising payouts in 2025 and an average growth rate of 4.86%. I identified 21 Aristocrats as both potentially undervalued and offering a projected long-term annualized return of at least 10%.

The magic of dividends is that you don't need to do anything to earn them aside from holding the stocks that pay them. Someone who accumulates enough dividend stocks could live off their portfolio's passive income stream and never have to work another day in their life.

Drug distributor Cardinal Health raised its annual adjusted profit forecast on Thursday, banking on demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.

Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.20 1 Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points)2 Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283 Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4 Raising lon...